Beyond Your Cancer

Isoray passionately designs and develops innovative and personalized brachytherapy products that effectively treat many forms of cancer. We believe in pioneering solutions for life beyond your cancer.

Patients Treated

Isoray Medical, Inc. is an innovative company that designs and develops state-of-the-art, personalized brachytherapy products that provide a more cost-effective cancer treatment. Isoray employs approximately 40 employees, dedicated to the introduction of a unique isotope for the treatment of both common and also difficult to treat cancers.

Based in Richland, in the shadow of the Hanford Nuclear Reservation, Isoray leveraged the expertise in the region to develop a proprietary process for manufacturing a sought after new medical isotope, Cesium 131 used in brachytherapy treatment of cancer. Brachytherapy is a technique that places radiation sources (“seeds’) as close as possible to the tumor site to destroy cancer cells.

Cesium 131 has unique characteristics that have evolved into an effective treatment for many types of cancer. Specifically, Cesium 131 is able to provide a highly targeted, fast-acting radiation treatment that is able to deliver its energy in a shorter time period than conventional external beam radiation therapy or other isotopes currently used in brachytherapy, which is not only more cost-effective but typically results in less treatment side-effects.

The initial application for Cesium 131 is for the treatment of localized prostate cancer. The fast-acting nature of the treatment allows men to quickly recover from short term side-effects from radiation and return to normal urinary, bowel and sexual function faster than with other brachytherapy isotopes. A growing body of literature supports faster recovery when Cesium 131 brachytherapy is utilized.

In addition to serving as a novel, more efficient alternative for prostate brachytherapy treatment, Cesium 131 is showing great promise in other applications that previously had limited treatment alternatives, including recurrent gynecological cancers, brain tumors, sarcomas and other aggressive and recurrent tumors. Leading medical centers, hospitals and clinics across the United States are now offering this breakthrough treatment for cancer patients.

The fast-acting nature of the Cesium 131 isotope is well-suited to provide additional targeted radiation at the time of surgery, allowing for the treatment of residual disease while limiting the dose to surrounding healthy tissues. In many cases, the radiation “boost” can be delivered before conventional external beam radiation could even be started — while still delivering higher therapeutic doses.

In the case of brain cancer treatment, Isoray has submitted a 510(k) application for a novel delivery system developed in conjunction with the Barrow Neurological Institute (Phoenix, AZ) and is also pursuing a unique code to provide reimbursement.

Another exciting new application is for the treatment of recurrent gynecological tumors. Physicians at the University of Kentucky are using Cesium 131 to treat women with a less invasive approach, which historically has required extensive, debilitating surgical procedures. Early results are promising.

Isoray Medical is the sole producer of Cesium-131 brachytherapy sources, which are expanding brachytherapy treatments for difficult to treat cancers. Isoray is dedicated to pioneering cost-effective solutions for life beyond a patient’s cancer.

Investors

Review our SEC Filings, Codes of Conduct, & Management Teams.

Careers

We are always looking for talented people to join our team.

Isoray Announces Record Third Quarter Fiscal 2019 Financial Results

Record Revenue and Gross Profit Revenue Increased 22% Year-Over-Year RICHLAND, WASHINGTON – May 9, 2019 -- Isoray, Inc. (NYSE AMERICAN: ISR), a...

Isoray To Announce Third Quarter Fiscal 2019 Financial Results on May 9, 2019

Conference Call is May 9 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – May 1, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology...

Isoray Collaborates With Texas Oncology to Fill Void in Training Programs For Next Generation of Brachytherapists

RICHLAND, WASHINGTON – April 16, 2019 – Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in brachytherapy powering...

Webinar: Transitioning Isotopes for Prostate Brachytherapy – April 17th, 2019

After nearly 10 years and more than 12,000 patients treated following its FDA approval for prostate cancer treatment, sufficient scientific data and...

Isoray Announces Second Quarter Fiscal 2019 Financial Results

Record Revenue and Gross Profit Revenue Increased 24% Year-Over-Year   RICHLAND, WASHINGTON - February 12, 2019 -- Isoray, Inc. (NYSE AMERICAN:...

Join Us at the Following Event

Recent News

Isoray Announces Record Third Quarter Fiscal 2019 Financial Results

Record Revenue and Gross Profit Revenue Increased 22% Year-Over-Year RICHLAND, WASHINGTON – May 9, 2019 -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body,...

Isoray Announces Second Quarter Fiscal 2019 Financial Results

Record Revenue and Gross Profit Revenue Increased 24% Year-Over-Year   RICHLAND, WASHINGTON - February 12, 2019 -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout...

Blu Build Featured on WCIV-TV in Charleston, SC

WCIV-TV reports on the world’s first use of the Blu Build Cesium-131 brachytherapy delivery system at Hollings Cancer Center. Here’s the story on this important medical advance for prostate cancer patients and the...

Blu Build Featured on WTAT-TV in Charleston, SC

The world’s first use of the Blu Build Cesium-131 brachytherapy delivery system to treat prostate cancer at Hollings Cancer Center is an important development for prostate cancer patients and their doctors....

IsoRay Names Jonathan Hunt New Chief Financial Officer

RICHLAND, WASHINGTON – December 3, 2018 – IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced that Jonathan Hunt has been named Chief Financial Officer...